ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient outcomes and systemic lupus erythematosus (SLE)"

  • Abstract Number: PP11 • 2018 ACR/ARHP Annual Meeting

    The Road Less Traveled– Nontraditional Approaches to Increased Patient Adherence and Positive Outcomes

    Carlene Harrison, AstraZeneca, Gaithersburg, MD

    Background/Diagnosis: African-American female diagnosed with SLE, Lupus Nephritis, Discoid Lupus, and Raynaud’s Phenomenon in 2011. Symptoms included joint pain, edema in the ankles, malar rash,…
  • Abstract Number: 1396 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with Specific Quality of Life Evolution in SLE Patients: A French Prospective Longitudinal Multicenter Study

    Hervé Devilliers1, Marie Corneloup2, Francois Maurier3, Denis Wahl4,5, Geraldine Muller6, Olivier Aumaître7, Pascal Sève8, Gilles Blaison9, Jean-Loup Pennaforte10, Thierry Martin11, Nadine Magy12, Sabine Berthier13, Laurent Arnaud14, Abderrahmane Bourredjem15 and Zahir Amoura16, 1Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France, 2Clinical epidemiology, Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, 21000 Dijon, France, 3Médecine interne, Hôpitaux Privés de Metz, Metz, France, 4CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, 5CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, 6Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 7CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 8Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 9Internal medicine departement, Colmar Hospital, Colmar, France, 10Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 11Cnrs UPR9021, Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, IBMC CNRS UPR9021, Strasbourg, France, 12Internal Medecine, CHRU Besançon, Besancon, France, 13Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 14Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 15Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, Dijon, France, 16Université Pierre et Marie Curie, Paris, France

    Background/Purpose: To analyze variables associated with evolution of disease-specific health related quality of life (HRQoL) in systemic lupus erythematosus (SLE) patients. Methods: We conducted a…
  • Abstract Number: 1397 • 2018 ACR/ARHP Annual Meeting

    Item Responses to Disease-Specific Quality of Life Questionnaires in the 18 Months Following a Flare in SLE: An Item Response Theory Analysis of a French Prospective Longitudinal Multicenter Study

    Marie Corneloup1, Francois Maurier2, Denis Wahl3, Geraldine Muller4, Olivier Aumaître5, Pascal Sève6, Gilles Blaison7, Jean-Loup Pennaforte8, Thierry Martin9, Nadine Magy10, Sabine Berthier11, Laurent Arnaud12, Abderrahmane Bourredjem13, Zahir Amoura14 and Hervé Devilliers15, 1Clinical epidemiology, Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, 21000 Dijon, France, 2Médecine interne, Hôpitaux Privés de Metz, Metz, France, 3CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, 4Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 6Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 7Internal medicine departement, Colmar Hospital, Colmar, France, 8Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 9Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, 10Internal Medecine, CHRU Besançon, Besancon, France, 11Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, 12Department of Rheumatology, Hôpitaux Universitaires de Strasbourg; INSERM UMR-S 1109, Strasbourg, France, 13Clinical investigation center, INSERM CIC-EC 1432, Dijon University Hospital, Dijon, France, 14Department of Internal Medicine, National referral center for systemic lupus erythematosus and anti-phospholipid syndrome, Pitie-Salpetriere University Hospital, Paris, France, 15Service de Médecine Interne et Maladies Systémiques, CHU de Dijon, Dijon, France

    Background/Purpose: To explore, at an item-level, the effect of disease activity (DA) on disease specific health related quality of life (HRQoL) factors in systemic lupus…
  • Abstract Number: 1404 • 2018 ACR/ARHP Annual Meeting

    Responsiveness of Promis (Patient Reported Outcomes Measurement Information System) Measures in a Multi-Racial, Multi-Ethnic Systemic Lupus Erythematosus (SLE) Cohort

    Patricia Katz1, Stephanie Rush2, Jinoos Yazdany3, Laura Trupin1, Louise Murphy4, Cristina Lanata1, Lindsey A. Criswell1 and Maria Dall'Era3, 1University of California San Francisco, San Francisco, CA, 2Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA

    Background/Purpose: Recent studies have demonstrated the reliability and validity of the NIH PROMIS (Patient-Reported Outcomes Measurement Information System) measures in SLE. Analyses of their responsiveness…
  • Abstract Number: 1696 • 2018 ACR/ARHP Annual Meeting

    Impact of Hurricane Maria on a Cohort of Systemic Lupus Erythematosus Patients from Puerto Rico

    Luis M. Vilá1, Yaritza Berríos-López1, Carla Santiago-Burgos1, Lorena González-Sepúlveda2, Ileana Vázquez-Otero1 and Elizabeth Brown3, 1Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, 2Puerto Rico Clinical and Translational Research Consortium, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, 3Department of Pathology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: On September 20, 2017, Puerto Rico was devastated by Hurricane Maria causing severe damage to the Island infrastructure and essential services such as electricity,…
  • Abstract Number: 2439 • 2018 ACR/ARHP Annual Meeting

    A Description of Contraception Practices in the Ohio State University Lupus Cohort

    Veronica Mruk1, Ashlee Weaver2, Alexa Zofia3, Emily Sullivan4, Kelly Morris5, Stacy P. Ardoin6, Elise Berlan7 and Alexa Meara8, 1The Nationwide Children's Hospital, Columbus, OH, 2The Ohio State University School of Medicine, Columbus, OH, 3The Ohio State University, Columbus, OH, 4The Ohio State Univeristy Wexner Medical Center, Columbus, OH, 5Rheumatology and Immunology, The Ohio State University, Columbus, OH, 6The Ohio State University Wexner Medical Center, Columbus, OH, 7Adolescent Medicine, Nationwide Children's Hospital, columbus, OH, 8Internal Medicine/Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease, which predominantly affects women and reaches peak incidence during reproductive years. Periods of high…
  • Abstract Number: 2911 • 2018 ACR/ARHP Annual Meeting

    Patient-Reported Outcomes Measurement Information System (PROMIS®) Global Health Short Form Is Responsive to Patient Reported Changes in SLE Health Status

    Shanthini Kasturi1, Jackie Szymonifka2, Jessica R. Berman3, Kyriakos A. Kirou3, Alana B. Levine3, Lisa R Sammaritano4 and Lisa A. Mandl4, 1Medicine/Rheumatology, Tufts Medical Center, Boston, MA, 2Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

    Background/Purpose: The accurate and efficient serial measurement of patient centered outcomes is a priority in the clinical care of SLE. Patient-Reported Outcomes Measurement Information Systems…
  • Abstract Number: 1264 • 2017 ACR/ARHP Annual Meeting

    Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests (CATs) in Systemic Lupus Erythematosus (SLE)

    Shanthini Kasturi1, Jackie Szymonifka2, Jessica R. Berman3, Kyriakos A. Kirou1, Alana B. Levine1, Lisa R. Sammaritano1 and Lisa A. Mandl1, 1Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY

    Background/Purpose: PROMIS CATs are precise measures of quality of life with construct validity in SLE. The longitudinal responsiveness (sensitivity to change) of PROMIS CATs in…
  • Abstract Number: 2263 • 2017 ACR/ARHP Annual Meeting

    Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus

    Sarah L. Patterson1, Gabriela Schmajuk2, Kashif Jafri3, Katherine D. Wysham3 and Patricia P. Katz4, 1Division of Rheumatology, University of California, San Francisco, San Francisco, CA, 2San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, San Francisco, CA, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

    Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of…
  • Abstract Number: 3233 • 2016 ACR/ARHP Annual Meeting

    Determinants of Pain, Fatigue, Physical Function and Social Participation in SLE Patients, Measured with Patient Reported Outcomes Measurement Information System (PROMIS®) Computerized Adaptive Tests

    Shanthini Kasturi1, Jayme C. Burket2, Jessica Berman1, Kyriakos A. Kirou1, Alana B. Levine1, Lisa R. Sammaritano1 and Lisa Mandl1, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Healthcare Research Institute, Hospital for Special Surgery, New York, NY

    Background/Purpose: Poor SLE outcomes have been associated with certain clinical and socio-demographic characteristics, but the determinants of patient reported outcomes (PROs) in SLE are unknown.…
  • Abstract Number: 2836 • 2014 ACR/ARHP Annual Meeting

    Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus

    Michelle Petri1, Renee S. Martin2, Colin Hislop2, Morton A. Scheinberg3 and Richard Furie4, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Anthera Pharmaceuticals Inc, Hayward, CA, 3Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, 4Division of Rheumatology and Allergy-Clinical Immunology, North Shore - Long Island Jewish Health System, Great Neck, NY

    Background/Purpose: To conduct secondary endpoint analyses of the effects of subcutaneously-administered blisibimod (A-623, AMG 623), an inhibitor of B-cell activating factor (BAFF), on patient-reported outcomes and…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology